Array's Three Value Drivers Align With Pfizer's Three Oncology Pillars In $11.4bn Deal
Pfizer is buying Array for a 62% premium, citing its Braftovi/Mektovi drug combo, pipeline of targeted cancer therapies and royalty revenue from partnered assets as key value drivers, aligning with the three pillars the big pharma recently outlined for its oncology strategy.
You may also be interested in...
Pfizer's Dolsten On Finding Ways To “Accelerate External Science”
Worldwide President of R&D Mikael Dolsten talked to Scrip about Pfizer's busy business development track record and the company's ambition to maintain its leadership in breast cancer.
Stockwatch: Coronavirus Distorts The Shape Of Pfizer Results
Pfizer’s results may have heralded a third-quarter stabilization of pandemic-related effects had the costs and expectations for its vaccine not hijacked sentiment.
Pfizer Oncology Pipeline Shows Pivot To Targeted Therapies
Pfizer was heavily invested in immuno-oncology combinations five years ago, but following setbacks, the pipeline has shifted considerably, shaped partly by the acquisition of Array.